Immunization Services Division, National Center for Immunization and Respiratory Diseases.
Clin Infect Dis. 2014 Jan;58(1):50-7. doi: 10.1093/cid/cit580. Epub 2013 Sep 17.
Influenza vaccination of healthcare personnel (HCP) is recommended in >40 countries. However, there is controversy surrounding the evidence that HCP vaccination reduces morbidity and mortality among patients. Key factors for developing evidence-based recommendations include quality of evidence, balance of benefits and harms, and values and preferences.
We conducted a systematic review of randomized trials, cohort studies, and case-control studies published through June 2012 to evaluate the effect of HCP influenza vaccination on mortality, hospitalization, and influenza cases in patients of healthcare facilities. We pooled trial results using meta-analysis and assessed evidence quality using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.
We identified 4 cluster randomized trials and 4 observational studies conducted in long-term care or hospital settings. Pooled risk ratios across trials for all-cause mortality and influenza-like illness were 0.71 (95% confidence interval [CI], .59-.85) and 0.58 (95% CI, .46-.73), respectively; pooled estimates for all-cause hospitalization and laboratory-confirmed influenza were not statistically significant. The cohort and case-control studies indicated significant protective associations for influenza-like illness and laboratory-confirmed influenza. No studies reported harms to patients. Using GRADE, the quality of the evidence for the effect of HCP vaccination on mortality and influenza cases in patients was moderate and low, respectively. The evidence quality for the effect of HCP vaccination on patient hospitalization was low. The overall evidence quality was moderate.
The quality of evidence is higher for mortality than for other outcomes. HCP influenza vaccination can enhance patient safety.
超过 40 个国家推荐医护人员(HCP)接种流感疫苗。然而,HCP 接种疫苗是否能降低患者发病率和死亡率的证据仍存在争议。制定基于证据的建议的关键因素包括证据质量、获益与危害的平衡以及价值观和偏好。
我们系统地检索了截至 2012 年 6 月发表的随机试验、队列研究和病例对照研究,以评估医护场所中 HCP 流感疫苗接种对患者死亡率、住院和流感发病的影响。我们使用荟萃分析汇总试验结果,并使用 GRADE(Grading of Recommendations Assessment,Development and Evaluation)方法评估证据质量。
我们共纳入 4 项群组随机试验和 4 项在长期护理或医院环境中进行的观察性研究。所有研究中全因死亡率和流感样疾病的风险比分别为 0.71(95%置信区间[CI],0.59-0.85)和 0.58(95% CI,0.46-0.73);全因住院和实验室确诊流感的汇总估计值无统计学意义。队列和病例对照研究表明流感样疾病和实验室确诊流感与接种疫苗存在显著的保护关联。无研究报告患者的不良反应。使用 GRADE 方法,HCP 接种疫苗对死亡率和患者流感病例的影响的证据质量为中等级别和低等级别,而对患者住院的影响的证据质量为低等级别。总体证据质量为中等级别。
证据质量对于死亡率的评估高于其他结局。HCP 流感疫苗接种可提高患者安全性。